IN8bio Inc.

INAB | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.09

+$0.01 (+0.93%)

At close: Sep 21, 2026, 3:59 PM ET

$1.06

-$0.03 (-2.75%)

After-hours: Sep 21, 2026, 4:10 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.93%

(1D)

Rating

Updated: Sep 8, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $10.45M

1D Range

1.06 1.09

52W Range

0.88 2.73

Valuation (TTM)

PE -0.39

PB 0.57

EV/EBITDA 0.31

Valuation (NTM)

Forward PE N/A

Forward PEG 0.04

Price Target $4

Cash Flow

FCF Yield -139.7%

SBC Adj. FCF Yield -160.3%

SBC Impact -14.8%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -56.6% | -22.8%

FCF 3Y | 5Y 27.2% | 6.2%

Returns

ROA -85.8%

ROE -91.2%

ROIC -91.7%

Financial Health

Net Cash

$15.78M

Current Ratio 8.21

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various for...

Sector Healthcare

Industry Biotechnology

Employees 18

IPO Date Jul 29, 2021

Website in8bio.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

+266.97%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞